160 related articles for article (PubMed ID: 34051683)
21. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
22. Early alteration in apparent diffusion coefficient and tumor volume in cervical cancer treated with chemoradiotherapy or radiotherapy: Incremental prognostic value over pretreatment assessments.
Watanabe Y; Nakamura S; Ichikawa Y; Ii N; Kawamura T; Kondo E; Ikeda T; Nomoto Y; Sakuma H
Radiother Oncol; 2021 Feb; 155():3-9. PubMed ID: 33039422
[TBL] [Abstract][Full Text] [Related]
23. MRI-based radiomics value for predicting the survival of patients with locally advanced cervical squamous cell cancer treated with concurrent chemoradiotherapy.
Zhang X; Zhao J; Zhang Q; Wang S; Zhang J; An J; Xie L; Yu X; Zhao X
Cancer Imaging; 2022 Jul; 22(1):35. PubMed ID: 35842679
[TBL] [Abstract][Full Text] [Related]
24. Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.
Ho JC; Allen PK; Bhosale PR; Rauch GM; Fuller CD; Mohamed AS; Frumovitz M; Jhingran A; Klopp AH
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):546-553. PubMed ID: 28011045
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of diffusion-weighted magnetic resonance imaging and
Park JJ; Kim CK; Park BK
Radiother Oncol; 2016 Sep; 120(3):507-511. PubMed ID: 26900089
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
27. Texture Analysis of Apparent Diffusion Coefficient Maps in Cervical Carcinoma: Correlation with Histopathologic Findings and Prognosis.
Yamada I; Oshima N; Miyasaka N; Wakana K; Wakabayashi A; Sakamoto J; Saida Y; Tateishi U; Kobayashi D
Radiol Imaging Cancer; 2020 May; 2(3):e190085. PubMed ID: 33778713
[TBL] [Abstract][Full Text] [Related]
28. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging.
Park JJ; Kim CK; Park SY; Simonetti AW; Kim E; Park BK; Huh SJ
Magn Reson Imaging; 2014 Oct; 32(8):993-1000. PubMed ID: 24970025
[TBL] [Abstract][Full Text] [Related]
29. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy.
Kim KA; Park MS; Ji HJ; Park JY; Han KH; Kim MJ; Kim KW
J Magn Reson Imaging; 2014 Feb; 39(2):286-92. PubMed ID: 24302545
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome.
Andersen EK; Hole KH; Lund KV; Sundfør K; Kristensen GB; Lyng H; Malinen E
Radiother Oncol; 2013 Apr; 107(1):117-22. PubMed ID: 23333024
[TBL] [Abstract][Full Text] [Related]
31. Predicting tumor recurrence in patients with cervical carcinoma treated with definitive chemoradiotherapy: value of quantitative histogram analysis on diffusion-weighted MR images.
Erbay G; Onal C; Karadeli E; Guler OC; Arica S; Koc Z
Acta Radiol; 2017 Apr; 58(4):481-488. PubMed ID: 27445314
[TBL] [Abstract][Full Text] [Related]
32. Voxelwise comparison of perfusion parameters estimated using dynamic contrast enhanced (DCE) computed tomography and DCE-magnetic resonance imaging in locally advanced cervical cancer.
Kallehauge J; Nielsen T; Haack S; Peters DA; Mohamed S; Fokdal L; Lindegaard JC; Hansen DC; Rasmussen F; Tanderup K; Pedersen EM
Acta Oncol; 2013 Oct; 52(7):1360-8. PubMed ID: 24003852
[TBL] [Abstract][Full Text] [Related]
33. Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy.
Lee J; Kim CK; Gu KW; Park W
Eur Radiol; 2019 Nov; 29(11):6256-6265. PubMed ID: 31016443
[TBL] [Abstract][Full Text] [Related]
34. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
35. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM
Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967
[TBL] [Abstract][Full Text] [Related]
36. MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach.
Laliscia C; Gadducci A; Mattioni R; Orlandi F; Giusti S; Barcellini A; Gabelloni M; Morganti R; Neri E; Paiar F
Tumori; 2022 Aug; 108(4):376-385. PubMed ID: 34235995
[TBL] [Abstract][Full Text] [Related]
37. Can diffusion-weighted magnetic resonance imaging predict tumor recurrence of uterine cervical cancer after concurrent chemoradiotherapy?
Bae JM; Kim CK; Park JJ; Park BK
Abdom Radiol (NY); 2016 Aug; 41(8):1604-10. PubMed ID: 27056747
[TBL] [Abstract][Full Text] [Related]
38. [Curative effect analysis of postoperative concurrent chemoradiotherapy on early-stage cervical cancer patients with intermediate-risk factors].
Tang Q; Tu YQ; Chen JH; Lyu XJ; Yan DD
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):462-466. PubMed ID: 29936774
[No Abstract] [Full Text] [Related]
39. Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer.
Surov A; Meyer HJ; Schob S; Höhn AK; Bremicker K; Exner M; Stumpp P; Purz S
Oncotarget; 2017 Apr; 8(17):28285-28296. PubMed ID: 28423698
[TBL] [Abstract][Full Text] [Related]
40. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
